Insulin therapy will lead hyperglycemia treatment sales through 2036 with 42.5% of the treatment segment in 2026. Oral administration leads the route of administration segment with a 63.8% share. The market was valued at USD 630.5 million in 2025, reaching USD 704.9 million in 2026 and USD 2,150.53 million by 2036.